Amphastar Pharmaceuticals, Inc. (AMPH) earnings date
Feb 25, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 37 days, typically, give or take 10 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 5, 2026 | after close | 36 | 8-K |
| Q2 FY2026 | Thu, Aug 6, 2026 | after close | 37 | 8-K |
| Q1 FY2026 | Thu, May 7, 2026 | after close | 37 | 8-K |
| Q4 FY2025 | Thu, Feb 26, 2026 | after close | 57 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | after close | 37 | 8-K |
| Q2 FY2025 | Thu, Aug 7, 2025 | after close | 38 | 8-K |
| Q1 FY2025 | Wed, May 7, 2025 | after close | 37 | 8-K |
| Q4 FY2024 | Thu, Feb 27, 2025 | after close | 58 | 8-K |
What they guided beta
| Q3 FY2026 | "Share Buyback Program On November 4, 2026, the Company’s Board of Directors authorized a $50 million increase to the Company’s share buyback program, which is expected to continue for an indefinite period of time." exhibit |
| Q3 FY2026 | "The Company is developing multiple proprietary products with injectable, topical and intranasal dosage forms. The Company’s proprietary pipeline also includes four in-licensed products including three proprietary peptides targeting oncology and ophthalmology indications, and a fully synthetic corticotropin compound designed to address inflammatory and autoimmune conditions. Conference Call Information The Company will hold a conference call to discuss its financial results today, November 5, 2026, at 2:00 p.m. Pacific Time. To access the conference call, dial toll-free (877) 407-0989 o" exhibit |
| Q2 FY2026 | "This was partially offset by: o The impact of lower average selling price for BAQSIMI ® , glucagon, and our epinephrine multi-dose vial product o Increased manufacturing expenses due to the expansion of our manufacturing facility in Rancho Cucamonga, CA Three Months Ended June 30, Change 2026 2025 Dollars % (in thousands) Selling, distribution, and marketing $ 13,335 $ 10,235 $ 3,100 30 % General and administrative 18,242 13,991 4,251 30 % Research and development 22,164 20,080 2,084" exhibit |
| Q2 FY2026 | "This increase was partially offset by a decrease in material and supply expenses. Three Months Ended June 30, Change 2026 2025 Dollars % (in thousands) Non-operating expenses: Interest income $ 2,287 $ 1,921 $ 366 19 % Interest expense (6,659) (6,281) (378) 6 % Other income (expenses), net 3,187 1,511 1,676 111 % Total non-operating expenses, net $ (1,185) $ (2,849) $ 1,664 (58) % The change in non-operating expenses, net, is primarily a result of " exhibit |
| Q2 FY2026 | "The Company is developing multiple proprietary products with injectable, topical and intranasal dosage forms. The Company’s proprietary pipeline also includes four recently in-licensed products including three proprietary peptides targeting oncology and ophthalmology indications, and a fully synthetic corticotropin compound designed to address inflammatory and autoimmune conditions. Conference Call Information The Company will hold a conference call to discuss its financial results today, August 6, 2026, at 2:00 p.m. Pacific Time. To access the conference call, dial toll-free (877) 407" exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/AMPH
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/AMPH
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/AMPH/"><img src="https://veritasdata.dev/embed/AMPH.svg" alt="AMPH earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/AMPH/)
Script
<script async src="https://veritasdata.dev/embed/AMPH.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/AMPH"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.